AMENDMENTS TO THE CLAIMS

The listing of the claims replaces all prior versions and listings of the claims for this application. Within this listing of the claims, the following amendments to the claims have been made: claims 23, 29, and 39 have been canceled; claims 1, 27, 30-32, 38, and 40 have been amended; and claims 41-44 are new.

1. **(currently amended)** A method for treating a patient suffering from or predisposed to developing [[alveolitis and]] interstitial lung disease (ILD), comprising administering to the patient a pharmaceutical formulation that comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations of any of the foregoing.

2. **(original)** The method of claim 1, wherein the active agent is *cis*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

3. **(original)** The method of claim 2, wherein the active agent is *cis*-resveratrol.

4. **(original)** The method of claim 2, wherein the active agent is a conjugate of *cis*-resveratrol and a mono- or di-saccharide.

5. **(original)** The method of claim 4, wherein the active agent is *cis*-resveratrol glucoside.

6. **(original)** The method of claim 1, wherein the active agent is *trans*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

7. **(original)** The method of claim 6, wherein the active agent is *trans*-resveratrol.

8. **(original)** The method of claim 6, wherein the active agent is a conjugate of *trans*-resveratrol and a mono- or di-saccharide.

9. **(riginal)** The method of claim 8, wherein the active agent is *trans*-resveratrol glucoside.

10. (**riginal)** The method of claim 1, wherein the active agent comprises a mixture of *cis*-resveratrol and *trans*-resveratrol.

11. **(original)** The method of claim 1, wherein the active agent is delivered orally.

12. **(original)** The method of claim 1, wherein the active agent is delivered by pulmonary administration.

13. **(original)** The method of claim 1, wherein the active agent is delivered parenterally.

14. **(original)** The method of claim 13, wherein the active agent is delivered to the alveoli.

15-23. **(canceled)**

24. **(original)** The method of claim 1, further comprising the co-administration of an additional active agent.

25. **(original)** The method of claim 24, wherein the formulation further includes an additional active agent.

26. **(original)** The method of claim 25, wherein the additional active agent is selected from the group consisting of glucocorticoids, non-steroidal antiinflammatory drugs, macrolide antibiotics, bronchodilators, leukotriene receptor inhibitors, cromolyn sulfate and combinations thereof.

27. **(currently amended)** The method of claim 26, wherein the additional active agent is selected from the group consisting of phosphodiesterase inhibitors, long acting **[[$_2]]** β_2 adrenergic agonists, and combinations thereof.

28. **(original)** The method of claim 27, wherein the additional active agent is selected from the group consisting of theophylline, salmetrol xinafoate, and a combination thereof.

29. **(canceled)**

30. **(currently amended)** The pharmaceutical formulation of claim [[29]] 32, in the form of a dry powder.

31. **(currently amended)** A pharmaceutical formulation for treatment of ~~alveolitis and interstitial lung disease (ILD)~~ **alveolar inflammatory disease** comprising a first active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations of any of the foregoing[[,]]; and a second active agent selected from the group consisting of [[glucocorticoids, bronchodilators,]] leukotriene receptor inhibitors[[, cromolyn sulfate,]] **and macrolide antibiotics,** and combinations thereof.

32. **(currently amended)** The formulation of claim 31, wherein the formulation further comprises **a long acting β adrenergic agonist as a third active agent and** a carrier suitable for pulmonary drug administration, and the formulation is administered via inhalation.

33. **(previously presented)** The formulation of claim 31, wherein the formulation is administered orally or parenterally.

34. **(canceled)**

35. **(previously presented)** The dry powder formulation of claim 30, wherein the carrier is a pharmaceutical sugar.

36. **(previously presented)** The dry powder formulation of claim 30, wherein the particles of the powder have a diameter from about 0.1 μm to about 65 μm.

37. **(canceled)**

38. **(currently amended)** The [[pharmaceutical formulation]] **method** of claim 1, wherein the ILD is fibrosing alveolitis, sarcoidiosis, or fibrotic lung disease.

39. **(canceled)**

40. **(currently amended)** The pharmaceutical formulation of claim [[31]] **41**, wherein the ILD is fibrosing alveolitis, sarcoidiosis, or fibrotic lung disease.

41. **(new)** The pharmaceutical formulation of claim 31, wherein the alveolar inflammatory disease is one of chronic obstructive pulmonary lung disease (COPD) or interstitial lung disease (ILD).

42. **(new)** The pharmaceutical formulation of claim 41, wherein the COPD is chronic bronchitis and emphysema.

43. **(new)** The pharmaceutical formulation of claim 31, wherein the macrolide antibiotics are selected from the group consisting of erythromycine, azithromycin, and clarithromycin.

44. **(new)** The pharmaceutical formulation of claim 31, wherein the long-acting β adrenergic agonist is salmeterol xinafoate.